Baxter launches Zosyn Premix in US for the treatment of multiple infections caused by susceptible bacteria.
Baxter International Inc. announced the U.S. launch of Zosyn (piperacillin and tazobactam) Injection. Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter’s proprietary single-dose Galaxy containers
The use of premixes, or ready-to-use formats of standard doses of commonly prescribed drugs, may offer operational efficiencies for healthcare providers. Compounding a drug for patient use is a multi-step, manual process that requires oversight by pharmacy staff. A ready-to-use product like Zosyn premix can simplify the preparation process and help improve patient safety by reducing the chance of contamination and avoiding potential dosing errors that may occur when medications are compounded.
Baxter will sell Zosyn premix in 2.25 g in 50 mL, 3.375 g in 50 mL, and 4.5 g in 100mL presentations. Like other medications in Baxter’s premix portfolio, Zosyn premixuses Baxter’s proprietary Galaxy container technology. Galaxy is a non-PVC and non-DEHP system that enables premixed medications to have a longer shelf life.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins